Jinzi Wu
Chief Executive Officer at ASCLETIS PHARMA INC.
Net worth: 58 M $ as of 2024-06-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Judy Hejingdao Wu | F | 50 |
Ascletis Pharmaceuticals Co., Ltd.
Ascletis BioScience Co., Ltd.
Gannex LLC
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | 10 years |
| Cheng Li | M | 67 |
Nanjing University
| 46 years |
| David Happel | M | 62 | 2 years | |
| Elizabeth Grammer | F | 60 | 3 years | |
| Lin Hua | F | 50 | 6 years | |
| Yizhen Wei | M | 49 | 6 years | |
| Joshua Zhongbao | M | - | 6 years | |
| Elizabeth Rozek | F | 53 | 1 years | |
| Zhi Ming Cheng | M | 62 |
Nanjing University
| 42 years |
| Victor Shi | M | - |
The BayHelix Group
| - |
| Jiong Gu | M | 51 | 6 years | |
| Guo-Liang Yu | M | 62 |
The BayHelix Group
| - |
| Eduardo Bruno Martins | M | 61 | 3 years | |
| Yan Yuemei | F | - | - | |
| Yun Zhang | F | 40 |
The BayHelix Group
| - |
| Yuan Hua Ding | M | 61 |
The BayHelix Group
| - |
| Handan He | M | - | 5 years | |
| Yi You Chen | M | - |
The BayHelix Group
| - |
| Marietta Wu | M | 56 |
The BayHelix Group
| - |
| Zhengqing Li | M | - | 5 years | |
| Ming Fai Chung | M | 45 | 2 years | |
| Wei Fu | M | 42 |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | - |
| Ming Guo | M | 67 |
The BayHelix Group
| - |
| Jian Fan | M | 67 |
Nanjing University
| 41 years |
| John Gargiulo | M | - | 2 years | |
| James Xue | M | 54 |
The BayHelix Group
| - |
| Yi Ning Zhao | M | 53 |
The BayHelix Group
| 13 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Gillis | M | 71 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 13 years |
| Joseph Oriti | M | 44 | - | |
| Philippe Calais | M | 65 |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Giancarlo Mocchi | M | 84 | 3 years | |
| Anthony Rimac | M | 60 | 1 years | |
| Richard la Rue | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Ji Shun Liu | M | 67 |
Nanjing University
| 9 years |
| Rolf M. Zinkernagel | M | 80 | 15 years | |
| Pierre Landolt | M | 77 | 22 years | |
| Ulrich Lehner | M | 78 | 13 years | |
| Zhen Hai Liang | M | 59 |
Nanjing University
| 7 years |
| Jin Xing Qi | M | 62 |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | - |
| Edward V. Fritzky | M | 73 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 8 years |
| Nicole T. Sweetland | M | - |
University of Arizona
| 4 years |
| Peter Atadja | M | 64 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | 24 years |
| Christine L. Salvesen | F | - |
University of Arizona
| 6 years |
| Hai Sang | M | 67 |
Nanjing University
| 6 years |
| Peter Kornicker | M | - | 20 years | |
| Haichuan Qian | M | - |
Nanjing University
| 7 years |
| Bosheng Zhou | M | 59 |
Nanjing University
| 7 years |
| Mathew Cherian | M | 59 | 30 years | |
| Long Quan Pan | M | 60 |
Nanjing University
| 6 years |
| Run Yu | M | 68 |
Nanjing University
| 18 years |
| Bradley Mitchell | M | - |
University of Arizona
| 7 years |
| Wei Dong Li | M | 56 |
Nanjing University
| 6 years |
| Dong Xiao Zhang | M | 58 |
University of Arizona
| 3 years |
| Daniel McEvers Mahoney | M | - |
University of Arizona
| 8 years |
| Richard Rodgers | M | 57 | 9 years | |
| Bonabes-Olivier de Rougé | M | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 5 years |
| Daniel Vasella | M | 70 | 17 years | |
| Stephen G. Sudovar | M | 77 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Peter Burckhardt | M | - | - | |
| Wayne P. Yetter | M | 78 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | - |
| Gordon Ringold | M | 73 | 14 years | |
| Paulo Costa | M | 73 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | 6 years |
| Alexandre F. Jetzer-Chung | M | 83 | 15 years | |
| Subhash Raghunath Gupte | M | 85 | 25 years | |
| James Young | M | 71 | 13 years | |
| Peggy Phillips | F | 70 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 6 years |
| Ayani Kurussi Ravi Nedungadi | M | 65 | - | |
| Chad W. Souvignier | M | - |
University of Arizona
| 5 years |
| Jason P. Ley | M | - |
University of Arizona
| 3 years |
| Xiao Kun Wang | F | 53 |
Nanjing University
| 4 years |
| Adrian Suherman | M | 51 |
University of Arizona
| 4 years |
| Cheng Bin Qiu | M | 60 |
Nanjing University
| 4 years |
| Shawn Davis | M | - |
University of Arizona
| 4 years |
| Neng Wang | M | 50 |
Nanjing University
| 4 years |
| Natalie Burkart | F | - |
University of Arizona
| 4 years |
| Wen Yan Zhuang | F | 57 |
Nanjing University
| 4 years |
| Cui Hua Yang | M | 53 |
Nanjing University
| 4 years |
| Hong Gao | M | 56 |
Nanjing University
| 3 years |
| Jian Ping Zhou | M | 61 |
Nanjing University
| 4 years |
| Chadd Mitchell Garcia | M | - |
University of Arizona
| 4 years |
| Hai Wen He | F | 54 |
University of Arizona
| 2 years |
| Kevin Eamigh | M | 53 |
University of Arizona
| 4 years |
| Bryce Hancock | M | - |
University of Arizona
| 4 years |
| Ning Mao | M | 69 |
Nanjing University
| 3 years |
| Yadong Ju | M | 71 |
Nanjing University
| 4 years |
| Jason Rowley | M | - |
University of Arizona
| 4 years |
| Kera Badalamenti | F | - |
University of Arizona
| 4 years |
| He Liang Fu | M | 63 |
Nanjing University
| 3 years |
| David Maggart | M | - |
University of Arizona
| 4 years |
| Jonathan A. Firestein | M | - |
University of Arizona
| 4 years |
| Kathy Masterson | F | - |
University of Arizona
| 4 years |
| Ying Lin Han | M | - |
Nanjing University
| 3 years |
| Sri Nagarajan | M | - |
University of Arizona
| 2 years |
| Yesim Tokat-Acikel | M | - |
University of Arizona
| 1 years |
| Sam A. Donaldson | M | - |
University of Arizona
| 3 years |
| Royce Thomas Weisenberger | M | 51 |
University of Arizona
| 4 years |
| Hong Lin Yuan | M | 57 |
Nanjing University
| 4 years |
| Li Lu | M | - |
Nanjing University
| 4 years |
| Scott Wood | M | - |
University of Arizona
| 4 years |
| James Sherrin | M | - |
University of Arizona
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 50 | 50.00% |
| China | 36 | 36.00% |
| Switzerland | 8 | 8.00% |
| Canada | 4 | 4.00% |
| India | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jinzi Wu
- Personal Network
